The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Shogo Kumagai(National Cancer Research Institute), Hiroyoshi Nishikawa(Immunité et Cancer), Vitaly Kochin(Nagoya University), Naoya Yamazaki(Tokyo National Hospital), Takuma Irie(Chiba Cancer Center), Takahiro Kamada(Chiba Cancer Center), Kohei Shitara(National Cancer Center Hospital East), Hibiki Udagawa(National Cancer Center Hospital East), Yuka Maeda(Chiba Cancer Center), Keiju Aokage(National Cancer Center Hospital East), Masahito Kawazu(Chiba Cancer Center), Yoshiko Takeuchi(Chiba Cancer Center), Yosuke Togashi(Okayama University), Kōichi Goto(National Cancer Center Hospital East), Masahiro Tsuboi(National Cancer Center Hospital East), Genichiro Ishii(Juntendo University), Takeshi Kuwata(National Cancer Center Hospital East), Takuma Shibahara(Hitachi (Japan)), Ayaka Tsuge(Chiba Cancer Center), Shigeyuki Matsui(Nagoya University), Keisuke Kirita(Hakodate Central General Hospital), Akihito Kawazoe(National Cancer Center Hospital East), Eri Sugiyama(Chiba Cancer Center), Kenta Nakama, Toshihide Ueno, Kota Itahashi(Chiba Cancer Center), Hitomi Nishinakamura(Chiba Cancer Center), Yasuho Yamashita(Hitachi (Japan)), Toshihiko Doi(National Cancer Center Hospital East), Hiroyuki Mano(National Cancer Research Institute), Shota Fukuoka(National Cancer Research Institute)
Nature Immunology
August 31, 2020
Cited by 810


Related Papers